For decades, ultrasound has been used to image organs such as the heart and kidneys, check blood flow, monitor the development of fetuses, reduce pain and even break up kidney stones.
Now, a Norwegian biotech company called Phoenix Solutions AS is working with the Translational Genomics Research Institute (TGen), a Phoenix, Arizona-based biomedical research facility, to test the use of these pulsed sound waves to direct and focus cancer drug therapies.
In laboratory tests, TGen will help analyze the effectiveness of a technology called Acoustic Cluster Therapy (ACT), a unique approach to targeting cancer cells by concentrating the delivery of chemotherapies, making them more effective and potentially reducing their toxicity.
Humanscan Co. Ltd., a South Korean manufacture of ultrasound diagnostic imaging, is developing clinically applicable hardware optimized for ACT, which TGen will then validate.
Phoenix Solutions is using funding from Innovation Norway to conduct this research in advance of pancreatic cancer clinical trials planned later this year.
“We are very pleased to receive this grant, which will enable us to develop and validate an optimal ultrasound platform for clinical use of ACT. In their respective fields, Humanscan and TGen both represent the cutting edge of science, and we are confident this will contribute to the clinical success of our program,” said Dr. Per Sontum, CEO of Phoenix Solutions.
TGen is a world leader in the development of novel therapeutics for the treatment of pancreatic cancer. The TGen team led the clinical development of one of the current standard-of-care regimens for this disease — nab-paclitaxel plus gemcitabine. TGen currently is involved in 13 pancreatic cancer clinical programs.
“We are pleased that this research program has become a reality, and look forward to working with ACT. The concept represents a novel approach to targeted drug delivery and looks very promising,” said Dr. Haiyong Han, a Professor in TGen’s Molecular Medicine Division and head of the Basic Research Unit in TGen’s Pancreatic Cancer Program.
Among the advantages of ultrasound technology: it is generally painless; non-invasive; does not require needles, injections or incisions; and patients are not exposed to ionizing radiation, making the procedure safer than diagnostic techniques such as X-rays and CT scans.
Humanscan CEO Sungmin Rhim said, “We are excited to enter into this collaboration with Phoenix (Solutions) and participate in the development of ACT. Ultrasound mediated, targeted drug delivery is an emerging therapy approach with great potential and we are delighted to be in the forefront of this development.”
Phoenix Solutions also is considering this technology for use in addressing other types of cancer, including: liver, prostate and triple-negative breast cancer; and other diseases, including those involving inflammation and the central nervous system.
The Latest on: Cancer drug delivery
via Google News
The Latest on: Cancer drug delivery
- Okayama University research: Nanotechnology for making cancer drugs more accessible to the brainon February 22, 2021 at 8:34 pm
In a study reported in the Journal of Controlled Release, researchers from Okayama University describe the use of nanocarriers in selectively transporting ...
- Celsion Corporation Receives FDA Fast Track Designation for GEN-1 in Advanced Ovarian Canceron February 22, 2021 at 2:06 pm
Celsion Corporation (NASDAQ: CLSN), a clinical stage development company focused on DNA based immunotherapy and next generation vaccines, today announced that it has received Fast Track designation ...
- FDA Grants Fast Track Designation to GEN-1 Immunotherapy for Treatment of Advanced Ovarian Canceron February 22, 2021 at 1:02 pm
Celsion Corporation announced that fast track designation was granted to their immunotherapy, GEN-1, to treat patients with advanced stage III or IV ovarian cancer.
- Celsion Surges as FDA Fast-Tracks Ovarian-Cancer Drugon February 22, 2021 at 7:17 am
Celsion shares jumped after the drugmaker received FDA Fast Track status for its Phase 2 treatment for advanced ovarian cancer.
- Investors pour $8M into Raleigh medical device startup; its drug delivery tech traces roots to UNC-CHon February 19, 2021 at 12:15 pm
Advanced Chemotherapy Technologies (ACT), a medical device startup developing a way to improve the treatment of pancreatic cancer, has added $2.5 million in funding to support clinical testing of its ...
- ACT bags cash to trial local iontophoresis chemotherapy deliveryon February 15, 2021 at 10:08 pm
Advanced Chemotherapy Technologies (ACT) has raised money to fund clinical development of its method for delivering gemcitabine directly to tumors. ACT sees the technology as a way to deliver a fatal ...
- Metal-Organic Framework Helps Achieve Better Results for Cancer Immunotherapyon February 15, 2021 at 8:04 am
A cancer immunotherapy drug loaded onto a metal-organic framework exhibits improved delivery as well as a steady release for treating leukemia.
- Injectable hydrogels of newly designed brush biopolymers as sustained drug-delivery vehicle for melanoma treatmenton February 15, 2021 at 2:53 am
Novel biocompatible and brush copolymers have been developed for cancer treatment using its controlled drug-release potential. Polyurethane graft on linear dextrin has been synthesized to control the ...
- MGC Pharmaceuticals launches new clinical study into brain cancer treatmenton February 14, 2021 at 4:58 pm
MGC Pharma (ASX:MXC) has a new clinical study into using its proprietary nano-delivery platform to treat glioblastoma an aggressive form of brain cancer.
via Bing News